| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-091 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于预计触发可转债转股价格向下修正条件 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 10.00 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 （二）可转债上市情况 经深圳证券交易所（以下简称"深交所"）"深证上〔2020〕523 号"文同意，公司 314,404 万元可转债于 2020 年 6 月 19 日起在深交所挂牌交易，债券简称"蓝帆转债"，债券代 码"128108"。 （三）可转债转股期限 根据《蓝帆医疗股份有限公司公开发行可转换公司债券募集说明书》（以下简称 "《募集说明书》"）的规定，本次发行的可转债转股期自可转债发行结束之日（2020 年 6 月 3 日 ...

丙烯日报 | 2025-11-21 丙烯下游整体开工环比上升 市场要闻与重要数据 丙烯方面：丙烯主力合约收盘价5871元/吨（+31），丙烯华东现货价5925元/吨（+0），丙烯华北现货价5940元/吨（-10）， 丙烯华东基差54元/吨（-31），丙烯华北基差56元/吨（-12）。丙烯开工率74%（-1%），中国丙烯CFR-日本石脑油CFR152 美元/吨（-5），丙烯CFR-1.2丙烷CFR45美元/吨（+1），进口利润-241元/吨（+9），厂内库存45040吨（-2150）。 丙烯下游方面：PP粉开工率47%（+3.02%），生产利润-210元/吨（+20）；环氧丙烷开工率75%（+0%），生产利润 647元/吨（+8）；正丁醇开工率82%（-2%），生产利润-295元/吨（+6）；辛醇开工率77%（+8%），生产利润-249元/ 吨（+57）；丙烯酸开工率73%（-2%），生产利润543元/吨（+0）；丙烯腈开工率80%（+1%），生产利润-316元/吨（-43）； 酚酮开工率79%（+12%），生产利润-415元/吨（+0）。 市场分析 周内上游检修增多，丙烯开工环比下滑，而下游复产整体开工回升， ...

Core Viewpoint - The article discusses the increasing adoption of cooking robots in the restaurant industry, driven by the need for efficiency and quality in food preparation, especially following the backlash against pre-prepared meals [6][13]. Group 1: Industry Trends - The restaurant industry is experiencing a transformation with the introduction of cooking robots, which can significantly enhance cooking speed and maintain food quality while reducing labor costs [7][19]. - The shift from traditional cooking methods to automated solutions is a response to the challenges of balancing speed, taste, and cost in food service [7][10]. - The backlash against pre-prepared meals has led to a surge in interest from restaurants in implementing cooking robots, with inquiries increasing nearly tenfold in the past month [7][13]. Group 2: Technological Advancements - Cooking robots utilize advanced technology, including multi-sensor systems and intelligent temperature control algorithms, to replicate the cooking techniques of skilled chefs [16][19]. - These robots can achieve precise temperature adjustments and consistent stirring, which are critical for traditional Chinese cooking [13][16]. - The integration of AI-driven platforms allows restaurants to customize cooking processes based on local tastes and dish characteristics, enhancing the overall dining experience [16][19]. Group 3: Cost Efficiency - The cost of a medium-sized cooking robot is approximately 60,000 yuan, with a lifespan of 8-10 years and a monthly operating cost of around 600 yuan, leading to significant savings in labor costs compared to traditional chefs [19]. - Over an 8-year period, a cooking robot can help reduce operational costs by 680,000 to 1,340,000 yuan, making it a financially attractive option for restaurants [19]. - The implementation of cooking robots in corporate cafeterias, such as those at major companies like Goer Group, has resulted in improved efficiency and reduced food waste by over 70% [26][28]. Group 4: Market Adoption - Major companies, including Goer Group and Muyuan Foods, are increasingly adopting cooking robots to meet the high demands of their employee dining services while ensuring food safety and quality [21][25]. - The trend indicates a broader acceptance of automation in food preparation, with robots becoming a key player in both restaurant kitchens and corporate dining facilities [26][28].

丙烯日报 | 2025-11-18 下游装置集中重启带动需求回升 市场要闻与重要数据 丙烯方面：丙烯主力合约收盘价5913元/吨（-4），丙烯华东现货价5900元/吨（+25），丙烯华北现货价5845元/吨（+40）， 丙烯华东基差-13元/吨（+29），丙烯华北基差-45元/吨（+53）。丙烯开工率74%（-1%），中国丙烯CFR-日本石脑油 CFR148美元/吨（-8），丙烯CFR-1.2丙烷CFR60美元/吨（-1），进口利润-279元/吨（+25），厂内库存47190吨（-2630）。 丙烯下游方面：PP粉开工率44%（+0.59%），生产利润-115元/吨（-40）；环氧丙烷开工率75%（+1%），生产利润310 元/吨（+58）；正丁醇开工率83%（-3%），生产利润-186元/吨（-25）；辛醇开工率69%（-2%），生产利润-280元/吨 （-28）；丙烯酸开工率75%（+3%），生产利润561元/吨（-18）；丙烯腈开工率79%（+1%），生产利润-242元/吨（-31）； 酚酮开工率67%（-9%），生产利润-415元/吨（+0）。 市场分析 局部PDH装置检修提振叠加下游装置重启带来需求 ...

Core Viewpoint - The company, Bluestar Medical (002382), confirmed that its production and operational activities are normal and have not triggered any risk warnings or delisting risk warnings according to the relevant regulations of the Shenzhen Stock Exchange [1] Group 1 - The company responded to investor inquiries on November 14, indicating compliance with stock exchange regulations [1] - There are currently no events that would lead to risk warnings or delisting risks for the company [1]

Core Insights - Transcatheter Aortic Valve Replacement (TAVR) has rapidly developed since its inception in 2002, becoming a crucial treatment for elderly patients with aortic stenosis (AS) and aortic regurgitation (AR) [1][7] - In 2024, TAVR procedures in China reached 17,232, marking a 24.2% increase from 2023, with a cumulative total of 55,083 procedures [1][7] - The TAVR market in China has grown from 40 million yuan in 2017 to over 1.8 billion yuan in 2024, achieving a compound annual growth rate of 71.7% [9][10] Industry Overview - TAVR is a minimally invasive procedure that involves delivering a compressed artificial aortic valve via catheter to replace a diseased valve [2] - The primary access route for TAVR is through the femoral artery (TF), accounting for 79.9% of procedures, followed by the apical approach at 18.4% [7][8] Surgical Outcomes - The success rate of TAVR devices has increased to 96.16% by 2024, with a declining trend in perioperative mortality rates [8] - The procedure's safety and effectiveness have improved, as evidenced by decreasing rates of postoperative complications [8] Regulatory Approvals - By September 2025, multiple TAVR systems have been approved in China, with companies such as Peijia Medical Technology and Shanghai MicroPort Medical Technology among the applicants [10][11] Future Trends - The TAVR patient demographic is becoming younger, with ongoing research focusing on lifecycle management strategies and new valve materials [11][12] - Advancements in artificial intelligence are expected to enhance preoperative imaging analysis, surgical decision-making, and postoperative risk assessment in TAVR procedures [12]

Group 1 - The core point of the article is that as of October 31, 2025, the number of shareholders for Bluestar Medical (002382) is projected to be 74,338 households [1]

Core Viewpoint - The company, Bluestar Medical, reported a decline in revenue and profit for the first three quarters of 2025, primarily due to challenges in its health protection division, particularly in glove production [1] Group 1: Revenue and Profit Decline - The decline in revenue and profit is mainly attributed to the health protection division, with significant impacts from the PVC glove segment due to tariff and cyclical pressures [1] - The global glove industry is experiencing historically low pricing, prompting the company to adjust its operational strategy to increase order prices, resulting in improved gross margins despite lower revenue [1] Group 2: Cost Management - The company has not increased its expenses; instead, total sales, management, and R&D expenses decreased by over 60 million yuan year-on-year, indicating successful cost reduction measures implemented since last year [1] Group 3: Strategic Initiatives - The management is actively addressing challenges posed by the new international trade environment through various strategies, including supply chain enhancements, product innovation, and efficiency improvements [1] - The cardiovascular division has seen significant revenue and profit growth, reflecting the company's past investments in high-value consumables and its efforts to build an international platform [1] Group 4: Future Outlook - The company plans to continue advancing its strategic initiatives across various segments, focusing on product development and market expansion to enhance operational efficiency and deliver satisfactory results [1]

Core Viewpoint - Bluefan Medical (002382) provided an update on shareholder numbers as of October 31, 2025, indicating a total of 74,338 shareholders [1][2]. Summary by Categories - **Company Information** - As of October 31, 2025, Bluefan Medical is projected to have 74,338 shareholders [2].

Core Viewpoint - Bluefan Medical (002382) confirmed that it is not currently using Minglue software for enterprise marketing, operational strategy design, or decision-making processes [1] Summary by Categories - **Company Response** - Bluefan Medical addressed investor inquiries regarding the use of Minglue software, stating that the company does not utilize this software at present [1]